Some people report mild issues such as injection-site irritation, headaches, nausea, fatigue, or water retention

related full-length recombinant thymosin beta-4 (a different formulation than the marketed TB-500 fragment) has also been examined in small human studies for cardiac and dermatologic indications Examined in preclinical models, including diabetic rat Achilles tendon and rat ligament-injury studies, for actin-binding, cell-migration, and angiogenic activity that researchers have proposed as a mechanism for tendon and ligament repair, though this literature remains comparatively sparse for musculoskeletal applications specifically Known risks and side effects: Because TB-500 is manufactured and sold without FDA oversight as a "research chemical," independent testing and industry reporting describe wide variability in purity (with some products measured well below labeled potency) and contamination with heavy metals or bacterial byproducts, unlike pharmaceutical-grade recombinant thymosin beta-4 used in registered clinical trials Thymosin beta-4's core mechanisms, angiogenesis and cell migration, are also pathways exploited by tumors

In research environments, BPC-157 are commonly explored for their influence on muscle recovery, tendon repair, and cellular regeneration mechanisms
At a meeting of the South London Medical Society in 1849, and subsequently, in a monograph in 1855, British physician Thomas Addison (17931860) at Guys Hospital in London described several cases with idiopathic anemia characterized by pallor, weakness, and progressively worsening health leading to death (139)
Enhances Muscle Preservation By inhibiting the enzyme nicotinamide N-methyltransferase (NNMT), it enhances cellular energy expenditure, encouraging the body to utilize stored fat as an energy source rather than breaking down muscle tissue
FDA & Other Regulatory Body Guidelines: In the USA, the FDA regulates the bacteriostatic water and sterile water used to be used for pharmaceutical and medical purpose